Seeking Outside Investment or Other Funding From Other US and Global Patriots for Self-Funded Safely2Prosperity, a Top Infectious Disease Spread Risk Management Company
By Dr. John Norris
Dr. John Norris is a former FDA COO and Harvard faculty member. He is a successful entrepreneur and expert in risk management for the "spread" of pathogens from bio attacks, whether nature-made or human-manufactured. And he has written over 120 articles and posts on this topic's different aspects and perspectives. On behalf of all people everywhere, Dr. Norris and his team have self-funded $1 million in cash and invested over $2 million in sweat equity to create the world’s best infectious disease-spread risk-management platform: VirusVigilant. Their mission is to save up to a million lives by the decade's end. They have their "fingers in the dike." But look to other "US and global patriots" to help prepare the US and the world for an eminent bio attack.
Introduction
As the world grapples with the ongoing but lower-scale remnants of the COVID-19 pandemic and significant threats of a terrorist group or hostile-nation bio attack, the importance of effective infectious disease spread risk management has become painfully evident. It's the spread that kills millions. The world is plagued with problems right now, but the risk of bio attack is the greatest. Yet, exhausted from years of the COVID-19 pandemic, many do not see this.
Politicians, government agency heads, and business executives are now more than ever seeking ways to protect their people, workforce, families, and investors/voters and minimize the impact of infectious diseases on their operations--or, if they do not intend to be reckless, they should be. This is where 'The Safely2Prosperity (S2P) Infectious Disease Risk Management Company' comes in--by offering the transformative potential of their innovative VirusVigilant platform as a solution.
However, S2P is currently self-funded to $1 million in cash and over $2 million in sweat equity. It seeks outside investment, large or small, or other funding, such as government or foundation grants, to develop further and expand its operations. S2P's product is completed. It's not just a concept. It's a reality, and it has been launched. It gives the world a "finger in the dike." We have done our job. It is time for other US and global patriots and savvy investors--and other funders to step up to the plate and help minimize deaths and other harm.
In this article, we will explore the reasons why seeking outside investment or other funding from other "patriots" is crucial for S2P and those at risk of bio attack around the world. We will also discuss potential avenues for securing this growth-related financial support. This short article will plant the seed for joining the effort in the minds of others worldwide. “Faith as small as a mustard seed can move mountains.”
Why Seek Outside Investment or Other Funding, Large or Small
Adding AI to Strategic Response Tools: The only reason we have not yet exercised our plan to add AI to our "strategic response tools" is because of its great expense in doing so. AI is a natural component of our platform. We now provide information regarding the spread of up to 24 infectious diseases, each selected by the CEO, COO, or other head. From this information, which is brilliantly calculated and communicated, leaders can make decisions regarding ongoing responses needed to prevent, mitigate, and or control the spread of disease pathogens post-attack within their nation or enterprise. AI will add a further dimension: giving leaders "learned advice" at a moment's notice of the next steps to consider taking as the attack evolves and new data becomes available.
Enhancing Marketing and Sales Achievements: To effectively compete in the market and acquire a significant market share, our goal worldwide, S2P needs to invest in marketing and sales leaders and teammates. This includes creating awareness about the VirusVigilant platform, conducting targeted marketing campaigns, and building strategic partnerships. Outside investors or other funders can provide the necessary capital to implement the robust marketing and sales strategies we have developed or new ones to expand S2P's customer base. We can only meet our mission of saving up to a million lives by the end of the decade if we have broad participation in the US and around the globe.
Scaling Operations: Safely2Prosperity's VirusVigilant platform can potentially revolutionize infectious disease spread risk management. However, to scale our operations, S2P requires additional resources that $1 million in cash and over $2 million in sweat equity self-funding alone may not be able to provide. Outside investment or other funding can allow S2P to hire and train more staff, acquire further advanced technology (beyond even AI, as discussed above), and expand our reach to a broader customer base, also as discussed above. At the very least, external funding, such as investments or other forms, would enable S2P to invest in more cutting-edge technologies and innovative solutions or create them, ensuring their VirusVigilant platform remains at the forefront of disease-spread science and technology.
Conducting Research and Development: Continuous research and development are essential for staying ahead in the field of infectious disease spread risk management strategies, science, and technology. With our broader team's help, we conceived, planned, invented, and developed VirusVigilant, the first of its kind in the world. Continuously conducting further research and development would enable us to "stay ahead of the power curve" and save an ever-increasing number of lives. By remaining at the cutting edge of disease-spread technologies and innovative solutions, S2P would also ensure their VirusVigilant platform remains at the forefront of disease spread prevention, mitigation, and or control. This is the best place to stay continuously, morally, ethically, legally, and financially.
Options for Seeking Outside Investment or Other Funding
Investors: S2P has been approached by several prospective large investors, but the timing needed improvement. We have now finished and launched our nation-level and/or enterprise-level infectious disease spread risk-management platform product: VirusVigilant. We were also unwilling to entertain smaller investors earlier because we were buried with new product research and development. Since we have now finished and launched our nation-level and/or enterprise-level infectious disease spread risk-management platform product, we will entertain exploratory requests from all potential significant investors. We are now able to entertain exploratory requests from them.
Foundations: We are not big fans of some foundations. They are not "humanity-first organizations." They lack a passion for saving lives. However, many more foundations are high on our list of organizations with which we aspire to partner. We'll be able to entertain exploratory requests from the latter. We hope to hear from them soon.
Family Offices: We are very interested in speaking with family offices. A few members of our leader's family have assembled significant wealth that has been used wisely to help others. We can entertain exploratory requests from them now.
Investment Bankers: We are very interested in speaking with investment bankers. A few members of our leader's family have served as investment bankers and assembled significant wealth that has been used wisely to help others. We are able to entertain exploratory requests from them now.
Venture Capitalists: One option for S2P is to consider receiving additional funding from venture capital firms specializing in healthcare or technology investments. These firms have the expertise and resources to provide significant funding and guidance to young companies like S2P. By showcasing the potential impact of its VirusVigilant platform and demonstrating a solid growth plan, S2P may attract the interest of venture capitalists looking to invest in "highly disruptive" health and healthcare technologies and or advanced national security and defense technologies. We can entertain exploratory requests from them now.
Government Sponsors of Grants/Programs: Governments worldwide have launched various grants and funding programs to support innovative businesses addressing significant societal challenges, especially health and healthcare services effectiveness and resource allocations--as well as national security and defense effectiveness of preparations and budgeting. Although VirusVigilant is not an FDA-regulated medical device, S2P fits roughly into such categories. By invitation, S2P can explore these opportunities and apply for grants that align with their mission and goals. Under grants or contracts, government funding can provide financial support and credibility to S2P's infectious disease spread risk management efforts. Obviously, saving lives and economies is the highest goal of countries, too. We are able to entertain exploratory requests from them now.
Strategic Partners: Partnering with established pharmaceutical, medical device, insurance (from health to liability to business interruption), banking, and healthcare organizations, including large drug store companies, seeking protection of their businesses or additional growth areas can bring financial support and valuable expertise to S2P. For example, by collaborating with hospitals, hospital systems, health systems, pharmaceutical companies, or other healthcare providers, S2P can tap into existing networks and access funding opportunities that may otherwise be unavailable. Strategic partnerships can also open doors for S2P to new markets and customer segments. We can now entertain exploratory requests from creative, thoughtful, and insightful potential strategic partners. We have many ideas on how our partners will benefit greatly--financially, reputation-wise, and mission-wise--and vice versa.
Benefits of Outside Investment or Other Funding
Accelerated Growth: External capital can enable S2P to grow and develop rapidly. With a solid financial foundation, we can expand our team, improve our technology, and scale our operations faster than relying solely on self-funding. Plus, we give others "opportunities to serve" our nation and the world. The threat of bio attack is significant, and there is no higher calling than protecting humanity.
Innovation and Research: Outside funding provides S2P with the means to invest in ongoing research and development. This ensures that the VirusVigilant platform remains at the cutting edge of infectious disease spread risk management, incorporating the latest advancements in technology and scientific knowledge--and inventing some more of our own.
Expertise and Guidance: While seeking outside funding, S2P can partner with investors and other funders who bring financial resources, as well as industry expertise and guidance. These funders can provide valuable advice, mentorship, and access to other, or newly created, especially for S2P, professional networks--enhancing S2P's chances of broad and deep US and international connectedness and success.
Market Expansion: With additional funding, S2P can independently extend its market reach and target a broader customer base. This will increase revenue streams and market dominance, establishing S2P as the acknowledged leading and ever-growing infectious disease spread risk management industry player. This is good for all those engaged with S2P, including its investors, other funders, and customers.
Conclusion
Seeking outside investment or other funding is a critical next step for Safely2Prosperity's "Infectious Disease Spread Risk Management Company" to fulfill its mission of providing highly effective solutions for disease spread prevention, mitigation, and or control needed to possibly save millions of lives in the coming years. With an innovative product like the VirusVigilant platform and a clear growth strategy, S2P can attract private and or public capital to scale its operations, invest in AI, research, and development, and expand its market presence. By exploring and accepting additional funding, such as from investors, foundations, family offices, venture capitalists, government sponsors of grants/programs, and strategic partners, S2P can secure the financial support needed to make an additional significant impact in the field of infectious disease spread risk management--and essential to fulfilling its large-scale life-saving mission.
The time for thoughtful, aggressive, and effective preparedness in the US and worldwide is now. External funding can play a crucial role in ensuring that S2P can continue to meet its goals of helping politicians, government agency heads, and business leaders (including leaders of not-for-profit businesses) protect their people, workforces, families, and investors/taxpayers, among many others--and of minimizing the impact of infectious disease spread on economies, businesses, and people worldwide. Again, "it's the spread that kills millions." We must all be extensively prepared to manage the spread. We need creative, thoughtful, and insightful risk-management strategies, plans, programs, systems, tools, and other risk-management mechanisms to do this properly. To fulfill our mission, we must save up to a million lives by the end of the decade--if not millions. To do that, we require additional funding from outside sources, including US and global patriots.
A Public Service Announcement by Safely2Prosperity and Its Executive Chairman, Dr. John Norris
We are pleased to cover this well-hidden story of bio attack reckless unpreparedness as a public service for the sake of our readers and all the people of the US and the world. We aim to have informed, educated, and committed leaders in the US and worldwide at all levels of society. We hope they buy our solution because it is the best. But if not, they must purchase "a" solution. Three alternative solutions are almost as good as S2P's VirusVigilant.
Safely2Prosperity (S2P) provides a "comprehensive infectious-disease spread risk-management solution," VirusVigilant, for politicians, business executives, government-agency heads, and other nation leaders to protect their people, employees, families, investors/taxpayers, and others. S2P's VirusVigilant "Infectious Disease Safety Program" (like a now-ubiquitous "Fire Safety Program" but much more sophisticated and complex) combines a SaaS platform with customized risk management tools (AI is to be added soon) for overseeing add-on packages of vaccinations, testing, therapeutics, isolation (if infected), quarantining (if exposed), and tracking technologies, among many others, for up to 24 infectious diseases and their most significant variants.
These tools help such leaders meet their moral, ethical, and legal responsibilities while protecting and enhancing population, workforce, family, and investor/taxpayer safety and productivity. Thereby, VirusVigilant helps assure (it's not "insurance," but "assurance," for leaders, so "they can sleep at night") at 1,000 times less the cost (Yes, 1,000 times less) than health insurance, high levels of (1) business continuity, (2) revenue, (3) profits, (4) investor and insurer financial protection, and (5) the overall effectiveness and survival of the enterprise and its workers, families, and investors/taxpayers. With a focus on proactive measures, S2P offers a cost-effective, low-cost (as low as pennies per employee per month), intuitive solution for risk-managing infectious disease spread. "Again, It's the spread that kills millions."
Dr. John Norris is a former FDA COO and Harvard faculty member. He is also a successful entrepreneur recognized as an expert in preventing, mitigating, controlling, and otherwise risk-managing the "spread" of infectious diseases. He has often published on this or related topics in a wide variety of publications, including as editor-in-chief of two academic journals, one at Harvard (the most successful publication of its kind worldwide, which he founded at Harvard some 50 years ago) and the other at Cornell. And gave many presentations on the need for change in health and healthcare systems, including some 300 presentations worldwide. Also, he helped reform the "regulatory procedures" used by the Joint Commission (which "regulates" hospitals, clinics, and nursing homes and the services they provide) and the US FDA (which regulates drug and medical device developers and the products they develop). Finally, he is a successful businessperson and entrepreneur. He and his former teammates sold one of their last start-ups for almost $2 billion in today's dollars.
As the historically world-renowned diplomat Benjamin Franklin said as he signed the US Declaration of Independence from England (the first, most costly, and most dangerous step in forming the United States as a country, but a critical step): "Gentlemen [and Ladies], we must all hang together, or, most assuredly, we shall all hang separately." Thoughtful and aggressive "preparedness" is the first and most essential step in protecting our people and those of our allies from the devastation of a bio attack by a terrorist group, such as Hamas, or a hostile nation, such as Iran. Preparedness costs as little as 60 cents per employee per month (again, 1,000th the monthly cost of health insurance). Yet bio attack risk management might prove far more valuable to workers, families, and investors--and eventually in far more demand. Therefore, politicians and other leaders who desire to retain their jobs will want to ensure they are always in place. Any leader who fails to protect those for whom they are responsible from the damage of a bio attack is likely to be found as "reckless."
If you want to learn more about VirusVigilant, please get in touch with Dr. John Norris by text at 617-680-3127 or by email at John.Norris@Safely2Prosperity.com (mailto: John.Norris@Safely2Prosperity.com). S2P's website is safely2prosperity.com (http://safely2prosperity.com/).
© 2024 Safely2Prosperity LLC and Dr. John Norris, Executive Chairman. ALL RIGHTS RESERVED.
Comments